134 related articles for article (PubMed ID: 24397259)
1. An update on the use of rifapentine for tuberculosis therapy.
Chan JG; Bai X; Traini D
Expert Opin Drug Deliv; 2014 Mar; 11(3):421-31. PubMed ID: 24397259
[TBL] [Abstract][Full Text] [Related]
2. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
[TBL] [Abstract][Full Text] [Related]
3. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
[TBL] [Abstract][Full Text] [Related]
4. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
Dorman SE; Savic RM; Goldberg S; Stout JE; Schluger N; Muzanyi G; Johnson JL; Nahid P; Hecker EJ; Heilig CM; Bozeman L; Feng PJ; Moro RN; MacKenzie W; Dooley KE; Nuermberger EL; Vernon A; Weiner M;
Am J Respir Crit Care Med; 2015 Feb; 191(3):333-43. PubMed ID: 25489785
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment.
Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
Eur J Pharm Biopharm; 2016 Oct; 107():205-14. PubMed ID: 27422209
[TBL] [Abstract][Full Text] [Related]
6. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
Dorman SE; Nahid P; Kurbatova EV; Goldberg SV; Bozeman L; Burman WJ; Chang KC; Chen M; Cotton M; Dooley KE; Engle M; Feng PJ; Fletcher CV; Ha P; Heilig CM; Johnson JL; Lessem E; Metchock B; Miro JM; Nhung NV; Pettit AC; Phillips PPJ; Podany AT; Purfield AE; Robergeau K; Samaneka W; Scott NA; Sizemore E; Vernon A; Weiner M; Swindells S; Chaisson RE;
Contemp Clin Trials; 2020 Mar; 90():105938. PubMed ID: 31981713
[TBL] [Abstract][Full Text] [Related]
7. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492
[TBL] [Abstract][Full Text] [Related]
8. Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.
Saini V; Ammerman NC; Chang YS; Tasneen R; Chaisson RE; Jain S; Nuermberger E; Grosset JH
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30936097
[TBL] [Abstract][Full Text] [Related]
9. Rifapentine for the treatment of pulmonary tuberculosis.
Munsiff SS; Kambili C; Ahuja SD
Clin Infect Dis; 2006 Dec; 43(11):1468-75. PubMed ID: 17083024
[TBL] [Abstract][Full Text] [Related]
10. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
Park SW; Tasneen R; Converse PJ; Nuermberger EL
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
[TBL] [Abstract][Full Text] [Related]
11. FDA approves rifapentine for the treatment of pulmonary tuberculosis.... Food and Drug Administration.
Roehr B
J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):19-25. PubMed ID: 11365728
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.
Zurlinden TJ; Eppers GJ; Reisfeld B
Antimicrob Agents Chemother; 2016 Aug; 60(8):4860-8. PubMed ID: 27270284
[TBL] [Abstract][Full Text] [Related]
13. Treatment of latent tuberculosis infection.
Parekh MJ; Schluger NW
Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy.
Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
Mol Pharm; 2016 Mar; 13(3):979-89. PubMed ID: 26808409
[TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
16. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report.
Tam CM; Chan SL; Lam CW; Leung CC; Kam KM; Morris JS; Mitchison DA
Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1726-33. PubMed ID: 9620898
[TBL] [Abstract][Full Text] [Related]
17. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.
Rifat D; Prideaux B; Savic RM; Urbanowski ME; Parsons TL; Luna B; Marzinke MA; Ordonez AA; DeMarco VP; Jain SK; Dartois V; Bishai WR; Dooley KE
Sci Transl Med; 2018 Apr; 10(435):. PubMed ID: 29618565
[TBL] [Abstract][Full Text] [Related]
19. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
[TBL] [Abstract][Full Text] [Related]
20. Inhalation of Respirable Crystalline Rifapentine Particles Induces Pulmonary Inflammation.
Parumasivam T; Ashhurst AS; Nagalingam G; Britton WJ; Chan HK
Mol Pharm; 2017 Jan; 14(1):328-335. PubMed ID: 27977216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
